Tallac Therapeutics
Sangeetha Bollini is an experienced professional in the field of preclinical operations and program management, currently serving as the Director of Preclinical Operations at Tallac Therapeutics since February 2021. Prior roles include Director of Program Management at ALX Oncology and a significant tenure at Pfizer as the Program Management and Assay Development Head, focusing on nonclinical pharmacology submissions. Sangeetha's career began with research at Harvard Medical School, contributing to studies on cell adhesion molecules. Additional experience includes protein engineering and assay development at Rinat Neuroscience and molecular biology at Deltagen. Sangeetha Bollini has a strong background in bioanalytical assays, regulatory operations, and multidisciplinary project management throughout various stages of drug development.
Tallac Therapeutics
Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development.